Arsanis to Present at the Needham & Company 17th Annual Healthcare Conference
March 20 2018 - 8:00AM
Business Wire
Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical
company focused on applying monoclonal antibody immunotherapies to
address serious infectious diseases, announced today that CEO René
Russo, PharmD, BCPS, will present a company overview at the Needham
& Company 17th Annual Healthcare Conference on March 27, 2018,
at 12:45 p.m. ET.
A webcast of the presentation will be available on the Arsanis
website under “Events and Presentations” or can be accessed at
http://wsw.com/webcast/needham86/asns/. The webcast will be
archived for 30 days following the live presentation.
About ArsanisArsanis, Inc. is a clinical-stage
biopharmaceutical company focused on applying monoclonal antibody
(mAb) immunotherapies to address serious infectious diseases. A
deep understanding of the pathogenesis of infection, paired with
access to some of the most advanced mAb discovery techniques and
platforms available today, has positioned Arsanis to
build and advance a pipeline of novel mAbs with multiple mechanisms
of action and high potency against their intended targets. The
company’s lead clinical program, ASN100, is aimed at serious
Staphylococcus aureus infections and is being evaluated in a
Phase 2 clinical trial for the prevention of S.
aureus pneumonia in high-risk, mechanically ventilated
patients. In addition to ASN100, the Arsanis preclinical pipeline
is comprised of mAbs targeting multiple serious bacterial and viral
pathogens, including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham,
Massachusetts, with European research and preclinical development
operations headquartered in Vienna, Austria (Arsanis
Biosciences GmbH).
For more information, please visit the Arsanis website at
www.arsanis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180320005486/en/
Media Contact:Ten Bridge CommunicationsKrystle Gibbs,
508-479-6358krystle@tenbridgecommunications.comorInvestor
Contact:Michael Gray, 781-819-5201Chief Operating and Chief
Financial Officermike.gray@arsanis.com
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
From Sep 2023 to Sep 2024